T1000	Negation 5424 5427	not
E1000	Negation:T1000 Scope:T1001
T1001	Span 5418 5434	(data not shown)
T1002	Negation 5621 5628	lacking
E1001	Negation:T1002 Scope:T1003
T1003	Span 5621 5628	lacking
T1004	Speculation 5709 5714	could
E1002	Speculation:T1004 Scope:T1005
T1005	Span 5709 5912	could be an important arbitrator of the upregulation of IL-17 in RA, on the basis of our experiments showing simultaneous blocking of NF-kappaB binding activity in the IL-17 promoter by PDTC and LY294002
T1006	Speculation 454 457	may
E1003	Speculation:T1006 Scope:T1007
T1007	Span 454 525	may have a role in the augmentation of rheumatoid synovial inflammation
T1008	Negation 531 535	lack
E1004	Negation:T1008 Scope:T1009
T1009	Span 531 563	lack of T cell-derived cytokines
T1010	Negation 1375 1378	not
E1005	Negation:T1010 Scope:T1011
T1011	Span 1369 1385	(data not shown)
T1012	Speculation 1072 1075	can
E1006	Speculation:T1012 Scope:T1013
T1013	Span 1034 1149	the highest level of IL-17 production can be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [25]
T1014	Speculation 1419 1424	might
E1007	Speculation:T1014 Scope:T1015
T1015	Span 1419 1500	might be due to increased cellular activity rather than to cellular proliferation
T1016	Negation 1463 1474	rather than
E1008	Negation:T1016 Scope:T1017
T1017	Span 1463 1500	rather than to cellular proliferation
T1018	Speculation 1939 1944	might
E1009	Speculation:T1018 Scope:T1019
T1019	Span 1939 2006	might produce a variety of proinflammatory cytokines and chemokines
T1020	Negation 1585 1588	not
E1010	Negation:T1020 Scope:T1021
T1021	Span 1585 1606	not the Th2 phenotype
T1022	Negation 3115 3118	not
E1011	Negation:T1022 Scope:T1023
T1023	Span 3115 3124	not do so
T1024	Negation 2966 2969	not
E1012	Negation:T1024 Scope:T1025
T1025	Span 2966 2993	not affect IL-17 production
T1026	Speculation 3209 3214	might
E1013	Speculation:T1026 Scope:T1027
T1027	Span 3209 3315	might exert effects indirectly on T cells through the activation of monocytes/macrophages in PBMC cultures
T1028	Negation 3151 3153	no
E1014	Negation:T1028 Scope:T1029
T1029	Span 3151 3158	no data
T1030	Negation 4009 4016	without
E1015	Negation:T1030 Scope:T1031
T1031	Span 4009 4028	without stimulation
T1032	Negation 3567 3569	no
E1016	Negation:T1032 Scope:T1033
T1033	Span 3567 3665	no data have been available on how IL-17 production can be regulated by certain signaling pathways
T1034	Speculation 4802 4808	seemed
E1017	Speculation:T1034 Scope:T1035
T1035	Span 4758 4905	The search for a downstream pathway of PI3K seemed to have a maximal response of Akt activation at 1 hour and a gradual loss of activity at 2 hours
T1036	Negation 4472 4475	not
E1018	Negation:T1036 Scope:T1037
T1037	Span 4448 4496	p38 MAPK activation was not affected by LY294002
T1038	Speculation 4982 4990	possible
E1019	Speculation:T1038 Scope:T1039
T1039	Span 4982 5042	possible involvement of PI3K in the induction of IL-17 in RA
T1040	Speculation 4969 4977	suggests
E1020	Speculation:T1040 Scope:T1041
T1041	Span 4969 5042	suggests the possible involvement of PI3K in the induction of IL-17 in RA
T1042	Negation 5385 5388	not
E1021	Negation:T1042 Scope:T1043
T1043	Span 5281 5434	the AP-1 signal transduction pathway, another important signaling pathway for cytokines/chemokines, was not activated in our experiments (data not shown)
T1044	Speculation 5170 5176	likely
E1022	Speculation:T1044 Scope:T1045
T1045	Span 5170 5266	likely that the NF-kappaB pathway is also actively involved in the induction of IL-17 in RA PBMC
